The estimated Net Worth of Yoseph Shaaltiel is at least $7.84 Milion dollars as of 15 September 2016. Yoseph Shaaltiel owns over 122,162 units of Protalix BioTherapeutics stock worth over $609,353 and over the last 17 years Yoseph sold PLX stock worth over $7,234,694.
Yoseph has made over 13 trades of the Protalix BioTherapeutics stock since 2007, according to the Form 4 filled with the SEC. Most recently Yoseph exercised 122,162 units of PLX stock worth $127,048 on 15 September 2016.
The largest trade Yoseph's ever made was selling 380,000 units of Protalix BioTherapeutics stock on 25 February 2010 worth over $2,679,000. On average, Yoseph trades about 59,523 units every 160 days since 2007. As of 15 September 2016 Yoseph still owns at least 585,916 units of Protalix BioTherapeutics stock.
You can see the complete history of Yoseph Shaaltiel stock trades at the bottom of the page.
Yoseph's mailing address filed with the SEC is C/O ORTHODONTIX, INC, 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL, L3, 20100.
Over the last 18 years, insiders at Protalix BioTherapeutics have traded over $46,705,936 worth of Protalix BioTherapeutics stock and bought 4,403,619 units worth $4,673,005 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Capital Management Lp Camber oraz Ltd Bio Cell. On average, Protalix BioTherapeutics executives and independent directors trade stock every 88 days with the average trade being worth of $404,231. The most recent stock trade was executed by Dror Bashan on 19 October 2023, trading 64,516 units of PLX stock currently worth $90,322.
protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher´s disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa‐galactosidase
Protalix BioTherapeutics executives and other stock owners filed with the SEC include: